DNTH
Dianthus Therapeutics, Inc.
A clinical-stage biotech developing antibody therapies for severe autoimmune diseases, Dianthus Therapeutics is built around its lead candidate, claseprubart, a selective C1s inhibitor designed for convenient subcutaneous self-injection and now in late-stage trials for conditions like generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. A second candidate, DNTH212, targets immune signals behind these diseases. The company holds worldwide development and commercial rights to its medicines outside Greater China.
CUSIP: 252828108HealthcareUS2 holders
Total Value
$2.94M
Total Shares
30.1K
Net Share Change
+5.2K
Activity
1 buying
Investor
Value
Shares
Weight
Change
